An appellate panel shut down a lawsuit from a compliance officer at Quest Diagnostics Inc. claiming the lab ran a fraudulent billing scheme for unnecessary tests.

Quest Diagnostics Inc. closed 8.75% short of its 52-week high of $182.38, which the company achieved on June 16th.

While clinical laboratory Quest Diagnostics (DGX) had a rough outing last week, speculators seeking a discount may want to ...

The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

Quest Diagnostics Incorporated (NYSE:DGX) is one of the 7 most undervalued pot stocks to buy according to analysts. On June ...

Quest Diagnostics (DGX) is a strong buy with growth potential, solid margins, and dividend increases. Discover the full ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the testing & diagnostics ...

Quest Diagnostics Inc. closed 5.99% below its 52-week high of $182.38, which the company achieved on June 16th.

New York Giants rookies officially report for training camp on Tuesday, one week ahead of the remainder of the team.

In the two weeks since Quest Diagnostics began processing novel coronavirus samples in its infectious disease lab, the private medical company has increased its capacity to 25,000 tests per day in ...

Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's disease protein that can appear years before dementia ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...